Showing results (131-140 of 288) with videos related to

Sort By:
Pageof 29
Cancers|October 27, 2022
Evolution of Head and Neck Cutaneous Squamous Cell Carcinoma Nodal Staging-An Australian PerspectiveMichael J L Hurrell, Tsu-Hui Hubert Low, Ardalan Ebrahimi, et al.
Clinical and Translational Radiation Oncology|April 17, 2018
Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiationYada Kanjanapan, Siddhartha Deb, Richard J Young, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2004
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapySherene Loi, Danny Rischin, Michael Michael, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 29, 2020
Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapyOlivia C Smibert, Cody C Allison, Marcel Doerflinger, et al.
Frontiers in Oncology|February 4, 2022
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell CarcinomaLuke S McLean, Annette M Lim, Angela Webb, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 19, 2015
Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcomeEdward E Graves, Rodney J Hicks, David Binns, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2016
Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART)Jolie Ringash, Richard Fisher, Lester Peters, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2018
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centreMichael Moloney, David Faulkner, Emma Link, et al.
Head & Neck|June 26, 2012
Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancerBena Cartmill, Petrea Cornwell, Elizabeth Ward, et al.
Investigational New Drugs|April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skinLuke S McLean, Tessa A Morris, Ann Gramza, et al.
Pageof 29